Trial of canakinumab, an IL-1 beta receptor antagonist, in patients with inclusion body myositis

Kosmidis, ML; Pikazis, D; Vlachoyiannopoulos, P; Tzioufas, AG; Dalakas, MC

Dalakas, MC (reprint author), Univ Athens, Dept Pathophysiol, Neuroimmunol Unit, Med Sch, Athens, Greece.; Dalakas, MC (reprint author), Thomas Jefferson Univ, Philadelphia, PA 19107 USA.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019; 6 (4):

Abstract

Objective To assess whether canakinumab, a monoclonal antibody against IL-1 beta approved for auto-inflammatory diseases, is effective as target-speci......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索